Published in Z Gastroenterol Verh on April 01, 1990
Drug interactions with cimetidine. Clin Pharmacokinet (1982) 2.49
Impaired cimetidine absorption due to antacids and metoclopramide. Eur J Clin Pharmacol (1981) 1.86
Pharmacokinetics of pindolol in man. Eur J Clin Pharmacol (1974) 1.46
Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet (1980) 1.42
Is radical scavenging necessary in the treatment of inflammatory bowel disease? Gastroenterology (1991) 1.39
[The duodenojejunal flexure--a gap in the routine diagnosis of gastrointestinal bleeding]. Dtsch Med Wochenschr (1999) 1.38
The effect of pindolol on exercise-induced cardiac acceleration in relation to plasma levels in man. Clin Pharmacol Ther (1975) 1.33
Clinical pharmacokinetics of cimetidine. Clin Pharmacokinet (1984) 1.32
Cimetidine for anastomotic ulcers after partial gastrectomy. A randomized controlled trial. N Engl J Med (1979) 1.32
Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology (1985) 1.29
Cimetidine plasma concentration-response relationships. Clin Pharmacol Ther (1981) 1.29
Effect of smoking on duodenal ulcer healing with cimetidine and oxmetidine. Gut (1982) 1.22
Disposition of quercetin in man after single oral and intravenous doses. Eur J Clin Pharmacol (1975) 1.21
Phenytoin: pharmacokinetics and bioavailability. Clin Pharmacol Ther (1976) 1.14
Single- and multiple-dose metronidazole kinetics. Clin Pharmacol Ther (1983) 1.09
Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease. Br J Clin Pharmacol (1978) 1.08
Inhibition of human liver cytochrome P-450 by omeprazole. Br J Clin Pharmacol (1986) 1.06
Pharmacokinetics of ketamine in man. Anaesthesist (1975) 1.03
Effect of in vivo elevation of free fatty acids on protein binding of drugs. Pharmacology (1974) 1.02
Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients. Clin Pharmacokinet (1980) 1.02
HJV gene mutations in European patients with juvenile hemochromatosis. Clin Genet (2005) 0.98
Does smoking interfere with the effect of histamine H2-receptor antagonists on intragastric acidity in man? Gut (1987) 0.97
Clofibrate disposition in renal failure and acute and chronic liver disease. Eur J Clin Pharmacol (1979) 0.95
Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. J Pharmacol Exp Ther (1975) 0.94
Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest (1975) 0.92
Drug protein binding and the nephrotic syndrome. Clin Pharmacokinet (1976) 0.92
Influence of thyroid status on plasma half-life of antipyrine in man. N Engl J Med (1974) 0.90
Comparative pharmacodynamics and plasma levels of beta-adrenoceptor blocking drugs. Br J Clin Pharmacol (1980) 0.90
Omeprazole inhibits elimination of diazepam. Lancet (1984) 0.90
Prediction of bioavailability for drugs with a high first-pass effect using oral clearance data. Eur J Clin Pharmacol (1982) 0.90
Clofibrate kinetics after single and multiple doses. Clin Pharmacol Ther (1978) 0.89
In vivo interactions between H2-receptor antagonists and ethanol metabolism in man and in rats. Hepatology (1985) 0.88
[Familial dwarfism with disproportionately high vertebral bodies]. Humangenetik (1972) 0.87
Effect of clofibrate on the metabolism of bilirubin, bromosulphophthalein and indocyanine green and on the biliary lipid composition in Gilbert's syndrome. Clin Sci (Lond) (1984) 0.87
Double-blind comparison of once-daily bopindolol, pindolol and atenolol in essential hypertension. Eur J Clin Pharmacol (1984) 0.87
Cimetidine interaction with liver microsomes in vitro and in vivo. Involvement of an activated complex with cytochrome P-450. Biochem Pharmacol (1985) 0.86
Disposition of valproic acid in man. Eur J Clin Pharmacol (1977) 0.85
[Purification and characterization of a 3'-phosphoadenylylsulfate: steroid sulfotransferase from human liver]. Biochim Biophys Acta (1970) 0.83
Gastric acid inhibition and oxmetidine kinetics in duodenal ulcer. Clin Pharmacol Ther (1982) 0.83
Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo. Pharmacol Ther (1987) 0.83
Single and multiple dose pharmacokinetics of pindolol. Eur J Clin Pharmacol (1978) 0.83
Superoxide inhibition following different stimuli of respiratory burst and metabolism of aminosalicylates in neutrophils. Dig Dis Sci (1994) 0.82
[Drugs interacting with coumarine oral anticoagulants (author's transl)]. Klin Wochenschr (1973) 0.82
Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection. J Viral Hepat (2004) 0.82
Effect of cimetidine on digoxin kinetics and creatinine clearance. Am Heart J (1984) 0.82
Sensitive high-performance liquid chromatographic method for the determination of metronidazole and metabolites. J Chromatogr (1983) 0.82
Diphenylhydantoin: correlation between protein binding and albumin concentration. Klin Wochenschr (1975) 0.81
Ultrasound-guided emergency endoscopic retrograde biliary drainage without radiography. Endoscopy (1997) 0.81
Serum-cholesterol-lowering effect of metronidazole and possible mechanisms of action. Klin Wochenschr (1985) 0.80
Analysis of DNA strand breaks, oxidized bases, and glutathione S-transferase P1 in human colon cells from biopsies. Cancer Epidemiol Biomarkers Prev (1999) 0.79
[Incidence of catechol-O-methyltransferase in human erythrocytes]. Arch Int Pharmacodyn Ther (1973) 0.79
Factors predicting the therapeutic outcome of duodenal ulcer treatment with H2-receptor antagonists. Klin Wochenschr (1985) 0.79
[Frequency of surgery in ulcer after the introduction of H2-blockers]. Dtsch Med Wochenschr (1984) 0.78
[Treatment failure of cimetidine in duodenal ulcer (author's transl)]. Dtsch Med Wochenschr (1982) 0.78
[Granulomatous colitis with pseudopolyp in schistosomiasis]. Dtsch Med Wochenschr (1989) 0.78
[Hepatic drug interactions]. Fortschr Med (1985) 0.78
[Purification and characterization of human placenta S-adenosylmethionine:catechol-O-methyltransferase]. Biochim Biophys Acta (1970) 0.78
Influence of phenobarbital treatment on cimetidine kinetics. Eur J Clin Pharmacol (1981) 0.78
Cimetidine pharmacokinetics and dosage requirements in children. Eur J Pediatr (1985) 0.77
The pharmacokinetic properties of beta adrenoceptor blocking drugs. Arch Int Pharmacodyn Ther (1980) 0.77
Cimetidine impairs nitrazepam clearance. Clin Pharmacol Ther (1983) 0.77
Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B. Hepatogastroenterology (1999) 0.77
Cimetidine excretion into breast milk. Br J Clin Pharmacol (1979) 0.76
Cimetidine disposition in obesity. Am J Gastroenterol (1984) 0.76
Clinical pharmacokinetics of hypolipidaemic drugs. Clin Pharmacokinet (1979) 0.76
Interaction between metronidazole and drugs eliminated by oxidative metabolism. Clin Pharmacol Ther (1985) 0.76
Superoxide, hydroxyl and fatty acid radical scavenging by aminosalicylates. Direct evaluation with electron spin resonance spectroscopy. Biochem Pharmacol (1992) 0.76
Altered disposition and availability of cimetidine in liver cirrhotic patients. Br J Clin Pharmacol (1982) 0.75
A prospective randomised trial on the effect of monitoring plasma anticonvulsant levels in epilepsy. J Neurol (1981) 0.75
Different iron-chelating properties of aminosalicylates. Gastroenterology (1992) 0.75
[Gastroscopy and rinsing of the gastric wall under sight in drug intoxication (author's transl)]. Leber Magen Darm (1978) 0.75
[Acetylcholinesterase and H2-receptor antagonists]. Z Gastroenterol (1984) 0.75
Protein binding of valproic acid in maternal and umbilical cord serum. Epilepsia (1984) 0.75
[Metabolic effects of antacids and interactions with other drugs]. Z Gastroenterol (1983) 0.75
[Cimetidine and recent H2-receptor blocking agents in the therapy of gastrointestinal diseases]. Med Welt (1982) 0.75
[Therapy of duodenal ulcer with low-dose antacids]. Dtsch Med Wochenschr (1984) 0.75
[Surgical treatment of ulcer disease 5 years before and after the introduction of cimetidine]. Z Gastroenterol (1983) 0.75
[Pharmacokinetic behavior of clofibrate in patients with kidney insufficiency]. Verh Dtsch Ges Inn Med (1978) 0.75
[Plasma level of pindolol (Visken) under long-term treatment, computed from pharmacokinetics after a single dose]. Verh Dtsch Ges Inn Med (1976) 0.75
[Oxmetidine--a new H2-receptor antagonist]. Dtsch Med Wochenschr (1983) 0.75
[Whipple's disease: an important differential diagnosis in polyarthritis and fever]. Dtsch Med Wochenschr (1984) 0.75
[Spontaneous perforation of the colon]. Med Welt (1982) 0.75
Sensitive gas-liquid chromatographic method for determination of valproic acid in biological fluids. J Chromatogr (1977) 0.75
[Therapy using beta-receptor blockaders. Side-effects and counterindications]. Internist (Berl) (1978) 0.75
Interaction between cimetidine and metronidazole. N Engl J Med (1983) 0.75
[Endoscopic diagnosis of hiatal hernias (axial and paraesophageal hernias)]. Chirurg (1978) 0.75
Clinical pharmacokinetics of cimetidine with observations on the plasma concentration-response curve. Methods Find Exp Clin Pharmacol (1981) 0.75
Endoscopic management of toxic masses in stomach. N Engl J Med (1977) 0.75
[Drug monitoring in intensive care]. Verh Dtsch Ges Herz Kreislaufforsch (1983) 0.75
The bioavailability of phenytoin. J Neurol (1977) 0.75
[Valproic acid in the treatment of epilepsy with special emphasis on serum level determination (author's transl)]. Fortschr Neurol Psychiatr Grenzgeb (1978) 0.75
[Relevant inhibition of acetylcholinesterase with H2-receptor antagonists]. Z Gastroenterol (1984) 0.75
[Topic Complex IV: Erosive reflux disease (ERD)]. Z Gastroenterol (2005) 0.75
[Stress studies of patients with coronary insufficiency receiving a beta blockader with reference to the beta-sympathicolytic blood level behavior]. Verh Dtsch Ges Inn Med (1978) 0.75
[Bioavailability of clofibrate. Comparative studies on Regelan and Bioscleran]. MMW Munch Med Wochenschr (1977) 0.75
[Drug monitoring in intensive care medicine]. Internist (Berl) (1984) 0.75
Interlaboratory variability of valproic acid determinations. Arzneimittelforschung (1977) 0.75
[Cimetidine: reduction of creatine clearance without modification of the digoxin kinetics]. Med Welt (1982) 0.75
[Drug dosing in chronic hepatic disease (author's transl)]. Leber Magen Darm (1981) 0.75
[The "Heidelberg model" of a program for continuing education]. Med Welt (1967) 0.75